Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07425587

Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study

The primary objective of this study is to establish an IL-6 concentration cutoff that predicts sepsis or septic shock (according to the Third International Consensus Definitions (Sepsis-3 criteria)) in patients who are admitted or are intended to be admitted to the hospital from the emergency department with suspected infection.

Recruiting

Interested in participating?

Request Info

Key information

Age range

22 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Florida College of Medicine, Gainesville, Florida, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients (≥22 years of age)
  • Intent to admit to hospital or admitted to the hospital via the emergency department
  • At least 0.6 mL plasma drawn (optimal 1 mL) and available for collection (or is anticipated to be able to be drawn and available) within 12 hours of (i.e., up to 12 hours after) presentation to the emergency department. For Cohort 1, Criterion #1 criteria should be met within 3 hours of sample collection (fresh or remnant).
  • Meets criteria for at least one of the 3 cohorts (patients may be included in more than one cohort) within 12 hours of emergency department presentation:
  • Cohort 1 (Systemic inflammatory response or culture ordered):
  • Criterion #1 (2 of below within 3 hours of sample collection, of which 1 is at least (A) or (B))
  • A) body temperature >38C or <36C,
  • B) HR>90 beats/min,
  • C) respiratory rate >20 breaths/min, or
  • D) white blood cell count > 12K or <4K/microliters or over 10% immature forms or bands) OR:
  • Criterion #2 (order for culture of a body fluid (e.g., blood, urine, sputum))
  • Cohort 2 (Treatment for suspected infection initiated):
  • Meets criteria for Cohort 1 and antimicrobials (antibiotics or antivirals) ordered.
  • Cohort 3 (Confirmed or strong evidence of infection):
  • Meets criteria for Cohorts 1 and 2, AND 1 or more of the following criteria:
  • Temp >101F (38.3C)
  • pneumonia by x-ray or CT,
  • Urinalysis with WBC>10/HPF;
  • Intraabdominal-pelvis infection by CT, U/S, or MRI
  • Skin / soft tissue infection by clinical exam
  • Evidence of meningitis on LP;
  • Positive microbiological culture (cultures drawn within 3 days of presentation)
  • Suspected line infection (e.g. redness or pus around the line)

Exclusion criteria

  • Prisoners or imprisonment at time of enrollment
  • Pregnant
  • Prior enrollment into this study
  • Informed consent as approved by IRB is unable to be obtained.
  • Environmental exposure (e.g., heat exposure)

Treatment and study plan

Primary outcomes

  1. Sepsis (according to the Third International Consensus Definitions (Sepsis-3 criteria)) within 3 days after inclusion.

    Time frame: Within 3 days after inclusion

Secondary outcomes

  1. In-hospital mortality up to 30 days

    Time frame: Within 30 days after inclusion

  2. In-hospital mortality up to 7 days

    Time frame: Within 7 days after inclusion

  3. Sequential Organ Failure Assessment (SOFA) score

    Time frame: Within 3 days after inclusion

    SOFA score has a range of 1 to 24, where higher scores represent higher degrees of single or multiple organ failure(s)

  4. Hospital Length of Stay

    Time frame: Participants will be followed up for hospital length of stay for up to 30 days

  5. ICU length of stay

    Time frame: Within 30 days after inclusion

  6. Bacterial vs viral infection (As assessed by cultures and/or viral testing)

    Time frame: Within 30 days after inclusion

    As assessed by cultures and/or viral testing.

  7. Progression to septic shock

    Time frame: Within 30 days after inclusion

    Participants will be followed up for progression to septic shock for up to 30 days

  8. 30-day all-cause mortality in patients with a final diagnosis of sepsis or septic shock

    Time frame: Within 30 days after inclusion

    Participants will be followed up for 30 days for all-cause mortality

  9. Initiation of vasopressor therapy (by hospital discharge or up to 30 days)

    Time frame: within 30 days after inclusion

  10. Initiation of renal replacement therapy (by hospital discharge or up to 30 days)

    Time frame: Within 30 days after inclusion

  11. Initiation of mechanical ventilation (by hospital discharge or up to 30 days)

    Time frame: Within 30 days after inclusion

  12. Free days from vasopressor therapy (by hospital discharge or up to 30 days)

    Time frame: Within 30 days after inclusion

  13. Free days from renal replacement therapy (by hospital discharge or up to 30 days)

    Time frame: Within 30 days after inclusion

  14. Free days from mechanical ventilation (by hospital discharge or up to 30 days)

    Time frame: Within 30 days after inclusion

  15. Free days from vasopressor therapy, renal replacement therapy, or mechanical ventilation, (by hospital discharge or up to 30 days)

    Time frame: Within 30 days after inclusion

Study contacts

Contact information is provided by the study sponsor or research team.

Clinical Affairs

CONTACT

[email protected]

844-327-7078

Sponsors and collaborators

Lead sponsor

Bluejay Diagnostics, Inc.

Industry

Registry information

Acronym: SYMON III

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Feb 23, 2026
Registry last updated
Jul 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.